Literature DB >> 10461022

Chronic central infusion of growth hormone secretagogues: effects on fos expression and peptide gene expression in the rat arcuate nucleus.

A R Bailey1, M Giles, C H Brown, P M Bull, L P Macdonald, L C Smith, R G Smith, G Leng, S L Dickson.   

Abstract

Growth hormone (GH) secretagogues induce GH release, in part, by direct actions upon anterior pituitary somatotropes and, in part, by actions upon the neuroendocrine circuitry that regulates GH secretion. In particular, acute systemic administration of GH secretagogues results in increased neuronal activity and Fos protein expression in the arcuate nucleus of the hypothalamus. Prolonged administration of GH secretagogues has been reported to have long-lasting effects upon GH release, promoting increased pulsatile secretion. Here, we investigated how chronic central infusion of GH secretagogues affects the response of arcuate nucleus neurons to acute systemic administration of GH secretagogues. In male rats, after central infusion of GH secretagogues for 5 days, there was no sustained expression of Fos in the arcuate nucleus, no significant induction of Fos expression in response to acute GH secretagogue challenge, and a greatly attenuated secretion of GH in response to acute GH secretagogue challenge, all reflecting loss of funtional responsiveness to GH secretagogues. In situ hybridisation revealed that, in the arcuate nucleus of GH secretagogue-infused rats, mRNA levels for GH-releasing hormone, neuropeptide Y and somatostatin were not different than in saline-infused animals. However, somatostatin mRNA levels in the periventricular nuclei of GH secretagogue-infused rats were significantly higher than those of saline-infused rats, indicating that this nucleus may play an important role in mediating the effects of chronic GH secretagogue administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10461022     DOI: 10.1159/000054462

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

1.  GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Authors:  J H A Oliveira; J G H Vieira; J Abucham; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs.

Authors:  K Malmlöf; M K Bauer; P B Johansen; M Ankersen; J D Veldhuis
Journal:  Endocrine       Date:  2001-12       Impact factor: 3.633

3.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

Review 4.  Physiological regulation of magnocellular neurosecretory cell activity: integration of intrinsic, local and afferent mechanisms.

Authors:  C H Brown; J S Bains; M Ludwig; J E Stern
Journal:  J Neuroendocrinol       Date:  2013-08       Impact factor: 3.627

Review 5.  Growth hormone secretagogues and hypothalamic networks.

Authors:  M T Bluet-Pajot; V Tolle; P Zizzari; C Robert; C Hammond; V Mitchell; J C Beauvillain; C Viollet; J Epelbaum; C Kordon
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

6.  Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.

Authors:  Junghun Lee; Ahreum Kwon; Hyun Wook Chae; Woo Jung Lee; Tae Hyuk Kim; Ho Seong Kim
Journal:  Yonsei Med J       Date:  2018-12       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.